Suppr超能文献

基于大麻的药物和大麻依赖:问题和证据的批判性回顾。

Cannabis based medicines and cannabis dependence: A critical review of issues and evidence.

机构信息

Drug Science, St Peter's House, London, UK.

Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.

出版信息

J Psychopharmacol. 2021 Jul;35(7):773-785. doi: 10.1177/0269881120986393. Epub 2021 Feb 17.

Abstract

Cannabis has been legalised for medical use in an ever-increasing number of countries. A growing body of scientific evidence supports the use of medical cannabis for a range of therapeutic indications. In parallel with these developments, concerns have been expressed by many prescribers that increased use will lead to patients developing cannabis use disorder. Cannabis use disorder has been widely studied in recreational users, and these findings have often been projected onto patients using medical cannabis. However, studies exploring medical cannabis dependence are scarce and the appropriate methodology to measure this construct is uncertain. This article provides a narrative review of the current research to discern if, how and to what extent, concerns about problems of dependence in recreational cannabis users apply to prescribed medical users. We focus on the main issues related to medical cannabis and dependence, including the importance of dose, potency, cannabinoid content, pharmacokinetics and route of administration, frequency of use, as well as set and setting. Medical and recreational cannabis use differs in significant ways, highlighting the challenges of extrapolating findings from the recreational cannabis literature. There are many questions about the potential for medical cannabis use to lead to dependence. It is therefore imperative to address these questions in order to be able to minimise harms of medical cannabis use. We draw out seven recommendations for increasing the safety of medical cannabis prescribing. We hope that the present review contributes to answering some of the key questions surrounding medical cannabis dependence.

摘要

大麻在越来越多的国家被合法化用于医疗用途。越来越多的科学证据支持将医用大麻用于一系列治疗适应症。随着这些发展,许多处方医生担心,增加使用量将导致患者出现大麻使用障碍。大麻使用障碍在娱乐性使用者中得到了广泛研究,这些发现经常被投射到使用医用大麻的患者身上。然而,探索医用大麻依赖的研究很少,衡量这一结构的适当方法也不确定。本文对当前的研究进行了叙述性综述,以了解在多大程度上、如何以及在多大程度上,娱乐性大麻使用者对依赖问题的担忧适用于规定的医用使用者。我们专注于与医用大麻和依赖相关的主要问题,包括剂量、效力、大麻素含量、药代动力学和给药途径、使用频率以及环境和情境的重要性。医用和娱乐性大麻的使用有很大的不同,这突出了从娱乐性大麻文献中推断研究结果的挑战。关于医用大麻使用是否会导致依赖,存在许多问题。因此,必须解决这些问题,以便能够将医用大麻使用的危害降到最低。我们提出了七点增加医用大麻处方安全性的建议。我们希望本综述有助于回答围绕医用大麻依赖的一些关键问题。

相似文献

5
Cannabis in patients with Parkinson's disease in Argentina. A cross sectional study.阿根廷帕金森病患者中的大麻。一项横断面研究。
Parkinsonism Relat Disord. 2020 Sep;78:66-67. doi: 10.1016/j.parkreldis.2020.06.033. Epub 2020 Jun 29.
7
Introduction to Cannabis Special Issue.大麻特刊引言。
J Dual Diagn. 2020 Jan-Mar;16(1):1-2. doi: 10.1080/15504263.2019.1708551. Epub 2020 Jan 6.
9
10
Cannabis and Epilepsy.大麻与癫痫
J Dual Diagn. 2020 Jan-Mar;16(1):75-82. doi: 10.1080/15504263.2019.1645372. Epub 2019 Aug 6.

引用本文的文献

本文引用的文献

5
Medical cannabis in the UK: From principle to practice.英国的医用大麻:从原则到实践。
J Psychopharmacol. 2020 Sep;34(9):931-937. doi: 10.1177/0269881120926677. Epub 2020 Jun 10.
7
A Balanced Approach for Cannabidiol Use in Chronic Pain.大麻二酚用于慢性疼痛的平衡方法。
Front Pharmacol. 2020 Apr 30;11:561. doi: 10.3389/fphar.2020.00561. eCollection 2020.
9
Mapping cannabis potency in medical and recreational programs in the United States.绘制美国医疗和娱乐用大麻效力图。
PLoS One. 2020 Mar 26;15(3):e0230167. doi: 10.1371/journal.pone.0230167. eCollection 2020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验